Information Provided By:
Fly News Breaks for September 11, 2019
Sep 11, 2019 | 16:29 EDT
Guggenheim analyst Dana Flanders initiated ANI Pharmaceuticals with a Buy rating and a $76 price target. The analyst likes ANI's "value buyer" approach, and noted that it is currently a buyer's market in generics. Flanders expects ANI the launch of vancomycin oral solution and gAggrenox in the second half of 2019, and sees an attractive growth outlook into 2020.
News For ANIP From the Last 2 Days
There are no results for your query ANIP